Palliativ kjemoterapi ved lungekreft
- Prosjektnummer
- 46018800
- Ansvarlig person
- Bjørn H. Grønberg
- Institusjon
- NTNU, IKM
- Prosjektkategori
- Phd-stipend 2007
- Helsekategori
- Cancer
- Forskningsaktivitet
- 6. Treatment Evaluation
Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
J Clin Oncol 2009 Jul;27(19):3217-24. Epub 2009 mai 11
PMID: 19433683
A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer.
Lung Cancer 2009 Jan;63(1):88-93. Epub 2008 jun 6
PMID: 18538889
Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung
Eur J Cancer 2010 Aug 46 (12):2225-34
A phase II study by the Norwegian Lung Cancer Group: Pemetrexed as second-line chemotherapy in recurrent small-cell lung cancer
Ann Oncol; 01.01.2006 - 31.12.2006 (Poster ESMO 2006)
Pemetrexed + carboplatin versus gemcitabine + carboplatin in the treatment of stage IIIB/IV non-small cell lung cancer
Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 7517 (Oral presentation ASCO 2.6.07)
A phase III study by the Norwegian Lung Cancer Group: Pemetrexed + carboplatin vs. gemcitabine + carboplatin as firstline chemot
Journal of Thoracic Oncology, Vol 2, No 8, Supplement 4, August 2007, S317-317 (Oral presentation World Conference on Lung Cancer 3.9.07)
The prognostic value of comorbidity assessed using the Cumulative Illness Rating Scale for Geriatrics (CIRS-G) in patients with
J Clin Oncol 26: 2008 (May 20 suppl; abstr 9506) (Oral presentation ASCO 31. May 2008)
A prospective phase II study: High-dose pemetrexed as second-line chemotherapy in small-cell lung cancer
Lung Cancer. 2009 Jan;63(1):88-93. Epub 2008 Jun 6
Pemetrexed in the treatment of advanced lung cancer
- Disputert:
- mars 2010
- Hovedveileder:
- Stein Sundstrøm
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Helse Midt-Norge RHF - Samarbeidsorganet og FFU